Nebulized aerosols containing nanoparticle dispersions
AssigneeElan Pharma International Limited
InventorsRay W. Wood, Lan DeCastro, H. William Bosch
Life of this patent
Estimating the term…
Abstract
There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble therapeutic or diagnostic agent particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment and diagnosis using the aerosol.
Claims30
A nebulized aerosol of a dispersion of liquid droplets, wherein:
- (a) the liquid droplets have a particle size of less than about ten microns in diameter;
- (b) the liquid droplets consist essentially of a liquid, a crystalline therapeutic agent, and at least one surface modifier;
- and
- (c) the aerosol is useful for delivery of the nanoparticles to the lungs of a mammal;
- wherein said nanoparticles consist essentially of:
- (i) crystalline particles of a therapeutic agent which is poorly soluble in said liquid, wherein the crystalline agent particles have an effective average particle size of less than about 1000 nm;
- and
- (ii) about 0.1 to 90% (w/w) of at least one surface modifier, based upon the combined weight of the surface modifier and the therapeutic agent, adsorbed on the surface of the crystalline therapeutic agent particles.
A nebulized aerosol of a dispersion of liquid droplets, wherein:
- (a) the liquid droplets have a particle size of less than about one micron in diameter;
- (b) the liquid droplets consist essentially of a liquid, a crystalline therapeutic agent, and at least one surface modifier;
- and
- (c) the aerosol is useful for delivery of the nanoparticles to the lungs of a mammal;
- wherein said nanoparticles consist essentially of:
- (i) crystalline particles of a therapeutic agent which is poorly soluble in said liquid, wherein the crystalline agent particles have an effective average particle size of less than about 1000 nm;
- and
- (ii) about 0.1 to 90% (w/w) of at least one surface modifier, based upon the combined weight of the surface modifier and the therapeutic agent, adsorbed on the surface of the crystalline therapeutic agent particles.
A method for making a nebulized aerosol of a dispersion of liquid droplets, wherein the aerosol is useful for delivery of the nanoparticles to the lungs of a mammal, wherein:
- (a) the liquid droplets have a particle size of less than about ten microns in diameter;
- (b) the liquid droplets consist essentially of a liquid, a crystalline therapeutic agent, and at least one surface modifier;
- and
- (c) the aerosol is useful for delivery of the nanoparticles to the lungs of a mammal;
- wherein said nanoparticles consist essentially of:
- (i) crystalline particles of a therapeutic agent which is poorly soluble in said liquid, wherein the crystalline agent particles have an effective average particle size of less than about 1000 nm;
- and
- (ii) about 0.1 to 90% (w/w) of at least one surface modifier, based upon the combined weight of the surface modifier and the therapeutic agent, adsorbed on the surface of the crystalline therapeutic agent particles.
A method of treating a mammal in need comprising delivering nanoparticles to the lungs of the mammal, wherein said method comprises the steps of:
- (a) forming a nebulized aerosol of an dispersion of liquid droplets, wherein the aerosol is useful for delivery of the nanoparticles to the lungs of a mammal, wherein:
- (i) the liquid droplets have a particle size of less than about ten microns in diameter;
- (ii) the liquid droplets consist essentially of a liquid, a crystalline therapeutic agent, and at least one surface modifier;
- and
- (iii) the aerosol is useful for delivery of the nanoparticles to the lungs of a mammal;
- wherein said nanoparticles consist essentially of:
- (i) crystalline particles of a therapeutic agent which is poorly soluble in said liquid, wherein the crystalline agent particles have an effective average particle size of less than about 1000 nm;
- and
- (ii) about 0.1 to 90% (w/w) of at least one surface modifier, based upon the combined weight of the surface modifier and the therapeutic agent, adsorbed on the surface of the crystalline therapeutic agent particles;
- and
- (b) administering said aerosol to the lungs of said mammal.
Dependencies are inferred from the claim text.